Deprexil in Subjects With Signs and Symptoms of Depression
Deprexil in Subjects With Signs and Symptoms of Depression
The purpose of the study is to assess the efficacy of DEPREXIL administration in combination
 with relaxation psychotherapy in the treatment of patients with signs and symptoms of
 depression. The duration of this double-blind placebo controlled phase 3 clinical trial will
 be 24 weeks. The estimated number of persons to be recruited and randomized for the study is
 200.
Inclusion Criteria:

 -  Mild or moderate symptoms and signs of depression for more than 3 months and less than
 3 years of duration.

 -  Signed informed consent

 Exclusion Criteria:

 -  Severe symptoms and signs of depression or Suicide proneness.

 -  Pregnancy or breastfeeding

 -  Receiving other experimental drug

 -  Use of anti-depressive medication within 15 days